What do systematic reviews say?

Fulvestrant vs other endocrine treatment

Fulvestrant showed no clear difference in arthralgia compared with other endocrine treatment (high certainty).

• Fulvestrant for hormone‐sensitive metastatic breast cancer 2017 · Cochrane Headline outcomes only
  RR 0.96 [0.86, 1.09]
  7 studies · 3244 participants
  High

Fulvestrant vs other endocrine treatment

Fulvestrant showed no clear difference in gynaecological toxicity compared with other endocrine treatment (high certainty).

• Fulvestrant for hormone‐sensitive metastatic breast cancer 2017 · Cochrane Headline outcomes only
  RR 1.22 [0.94, 1.57]
  6 studies · 2848 participants
  High

Fulvestrant vs other endocrine treatment

• Fulvestrant for hormone‐sensitive metastatic breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 4 participants
  High

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 764 participants
  Moderate

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 299 participants
  Moderate

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 111 participants
  Very low

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 308 participants
  Low

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 253 participants
  Low

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 213 participants
  Low

Intervention not reported

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 127 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Home‐based multidimensional survivorship programmes for breast cancer survivors 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Online support groups for women with breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Online support groups for women with breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Online support groups for women with breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 58 participants
  Low

Intervention not reported

• Online support groups for women with breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 120 participants
  Very low

Intervention not reported

• Online support groups for women with breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 140 participants
  Very low

Intervention not reported

• Online support groups for women with breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 78 participants
  Low

Boost vs no boost

Boost may leads to lower local control: recurrence at 5 years compared with no boost (low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 0.64 [0.55, 0.75]
  5 studies · 8315 participants
  Low

Boost vs no boost

Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 1.04 [0.94, 1.14]
  2 studies · 6342 participants
  Moderate

Boost vs no boost

Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).

• Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
  HR 0.94 [0.87, 1.02]
  3 studies · 6549 participants
  Low